The firm said that its platform successfully detected pathogens and resistance markers at limits of detection as low as 1 CFU/ml in spiked blood samples.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.
The London-based firm plans to fund development and clinical trials for its point-of-care diagnostic test for serious blood infections.
DNAe will combine its semiconductor DNA sequencing technology with nanoMR's PCS technology for a complete blood-to-result solution.
NEW YORK (GenomeWeb) – London-based DNA Electronics is developing a point-of-care diagnostic platform that can amplify, genotype via real-time PCR, and do targeted semiconductor sequencing all on one chip.
Cepheid said this week that it has appointed Peter Farrell as executive vice president of international commercial operations.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.